Company profile
UK company 08446072, incorporated on 15 March 2013.
Puridify LTD. is a UK company with status active founded in 2013 based in East of England.
Company number 08446072
Updated 07 Jul 2026 09:49
Reference milestones and recent Companies House filing stream events.
Company registered at Companies House
1 Apr 2018 to 31 Mar 2019
Gene therapy is an exciting new wave of medicine whereby therapeutic DNA is delivered into patients' cells to correct genetic disorders, use the body's own cells to make therapeutic proteins, or empower one's immune system to better fight cancer. Development of these advanced therapies is however still at a relatively early stage and current manufacturing...
1 Jan 2016 to 30 Sep 2017
Global demand for cheaper biotherapeutics drives the need for a reduction in manufacturing costs. Rapid advances in recombinant production technologies are offering new therapeutic possibilities in the treatment of illnesses such as haemophilia, Parkinson’s, and cancer. However, purification of these next generation protein therapeutics is extremely chall...
1 Apr 2015 to 31 Mar 2017
Global demand for cheaper biotherapeutics, which represent many of the new tools in the fight against diseases such as cancer and neurodegenerative conditions, drives the need for a reduction in manufacturing costs. A significant proportion of current costs arise from the purification technologies used to ensure the safety and efficacy of these treatments...
1 May 2014 to 31 Oct 2015
Global demand for cheaper biotherapeutics, which represent many of the new tools in the fight against diseases such as cancer, drives the need for a reduction in manufacturing costs. A significant proportion of current costs arise from the purification technologies currently used to ensure the safety and efficacy of these treatments. Improvements to these...
1 Feb 2014 to 31 Oct 2014
This project seeks to apply a novel nanofibre material to industrial biocatalysis for the first time. The goal being to reduce the costs and environmental impact compared to traditional chemical synthesis. The results of the project will be a global product delivering revenues to two UK based companies who will re-invest the proceeds in research and devel...
1 Oct 2013 to 30 Jun 2014
Global demand for cheaper biotherapeutics, which represent many of the new tools in the fight against diseases such as cancer, drives the need for a reduction in manufacturing costs. A significant proportion of current costs arise from the purification technologies currently used to ensure the safety and efficacy of these treatments. Improvements to these...
